Wilson's disease affects an estimated 1 in 30,000 people and is highly treatable when caught early, but delayed diagnosis can lead to irreversible liver failure, neurologic disability, or death. Confirmed cases have been reported in patients in their 70s and 80s, and late-onset disease may present with neurologic or psychiatric findings rather than obvious hepatic disease. AAVBC's stance is that age alone should never be used to exclude this disease. Unexplained liver disease, movement abnormalities, psychiatric change, or a mixed hepatic-neuropsychiatric presentation should prompt copper studies and specialist coordination.
AAVBC's Wilson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering confirmed disease coding and systemic manifestations, HCC/RAF V28 mapping, diagnostic assessment with the Leipzig Score, acute liver failure prognostication with the New Wilson Index, MEAT documentation, treatment escalation, chelation and zinc-therapy safety, comorbidity screening, and referral and follow-up timing, grounded in AASLD 2022 guidance.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Wilson's disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Wilson's disease affects an estimated 1 in 30,000 people and is highly treatable when caught early, but delayed diagnosis can lead to irreversible liver failure, neurologic disability, or death. Confirmed cases have been reported in patients in their 70s and 80s, and late-onset disease may present with neurologic or psychiatric findings rather than obvious hepatic disease. AAVBC's stance is that age alone should never be used to exclude this disease. Unexplained liver disease, movement abnormalities, psychiatric change, or a mixed hepatic-neuropsychiatric presentation should prompt copper studies and specialist coordination.
AAVBC's Wilson's Disease Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering confirmed disease coding and systemic manifestations, HCC/RAF V28 mapping, diagnostic assessment with the Leipzig Score, acute liver failure prognostication with the New Wilson Index, MEAT documentation, treatment escalation, chelation and zinc-therapy safety, comorbidity screening, and referral and follow-up timing, grounded in AASLD 2022 guidance.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Wilson's disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
